Clear Program Physician Webpage
Information specifically for physicians to help your patient understand PAD. Learn More »
Chronic Limb-Threatening Ischemia (CLTI) is a severe form of peripheral artery disease (PAD) that can lead to amputation and increased mortality/cardiovascular events.1 Now, Abbott's Esprit™ BTK System offers a breakthrough innovation for you and your patients as the first-and-only FDA-approved drug-eluting resorbable scaffold for CLTI. The only BTK device that does it all:
In the LIFE-BTK Trial, Esprit™ BTK demonstrated superior efficacy compared to PTA at the 1-year mark, with a 30.8% improvement in primary patency and limb salvage, establishing a new standard of care for infrapopliteal arterial disease in patients with chronic limb-threatening ischemia (CLTI).6
The 2-year results from the LIFE-BTK Trial, presented at VIVA 2024, showed a sustained improvement with Esprit™ BTK compared to PTA, with a 28.7% improvement in primary patency and limb salvage, and a comparable safety profile through two years.7
Esprit™ BTK significantly reduced the rate of clinically-driven target lesion revascularization (CD-TLR), with 48% fewer patients requiring repeat interventions compared to PTA.7
Watch how the Esprit™ BTK System does it all for CLTI: addressing vessel recoil and dissection,2 combined with a drug to inhibit neointimal hyperplasia,4 and then fully resorbs over time,5 preserving future treatment options.
Physicians share their experience with the Esprit™ BTK System and the advantages it delivers in treating their patients and improving outcomes.
The coding and reimbursement guide listed below is applicable to lower extremity endovascular procedures in the tibial/peroneal arteries using the Esprit™ BTK Ssytem. Esprit™ BTK can be performed in the hospital inpatient, hospital outpatient, ASC, and office-based labs (OBL) settings.
Hospital inpatient rates are applicable for Sept. 30, 2024 - Oct. 1, 2025. Hospital outpatient, ASC, and OBL rates are applicable for Jan. 1 - Dec. 31, 2025.
Hospital Inpatient8 BTK Procedures
MS-DRG | DESCRIPTION | FY 2025 MEDICARE NAT'L RATE |
---|---|---|
BTK STENTING | ||
252 | Other vascular procedures w/ MCC | $24,413 |
253 | Other vascular procedures w/ CC | $18,169 |
254 | Other vascular procedures without CC/MCC | $12,450 |
BTK ATHERECTOMY | ||
270 | Other major cardiovascular services w/ MCC | $36,530 |
271 | Other major cardiovascular services w/ CC | $24,514 |
272 | Other major cardiovascular services without CC/MCC | $17,807 |
Hospital Outpatient9 BTK Procedures
APC | DESCRIPTION | 2025 MEDICARE NAT'L RATE |
---|---|---|
5193 | Level 3 Endovascular Procedures
| $11,341 |
5194 | Level 4 Endovascular Procedures
| $17,957 |
OBL10 BTK Procedures
CPT‡13 | DESCRIPTION | 2025 MEDICARE NAT'L RATE |
---|---|---|
37228 | Angioplasty | $3,752 |
37229 | Atherectomy | $8,070 |
37230 | Stenting | $8,076 |
37231 | Stenting and atherectomy | $10,596 |
ASC11 Procedures
CPT‡13 | DESCRIPTION | 2025 MEDICARE NAT'L RATE |
---|---|---|
37228 | Angioplasty | $6,603 |
37229 | Atherectomy | $11,855 |
37230 | Stenting | $11,439 |
37231 | Stenting and atherectomy | $12,261 |
See the Vascular Health Economics and Reimbursement website for additional resources
The material and the information contained herein is for general information purposes only and is not intended, and does not constitute, legal, reimbursement, business, clinical or other advice. Furthermore, it is not intended to and does not constitute a representation or guarantee of reimbursement, payment, or charge, or that reimbursement or other payment will be received. It is not intended to increase or maximize payment by any payer. Abbott makes no express or implied warranty or guaranteed that the list of codes and narratives in this document is complete or error-free. Similarly, nothing in this document should be viewed as instructions for selecting any particular code, and Abbott does not advocate or warrant the appropriateness of the use of any particular code. The ultimate responsibility for coding and obtaining payment/reimbursement remains with the customer. This includes the responsibility for accuracy and veracity of all coding and claims submitted to third-party payers. In addition, the customer should note that laws, regulations, and coverage policies are complex and are updated frequently, and therfore, the customer should check with its local carriers or intermediaries often and should consult with legal counsel or a financial, coding, or reimbursement specialist for any questions related to coding, billing, reimbursement, or any related issues. This material reproduces information for reference purposes only. It is not provided or authorized for marketing use.
Diameter | 18 | 28 | 38 | Sheath (F) | Maximum Post-Dilation Diameter | Nominal/RBP Inflation Pressure |
---|---|---|---|---|---|---|
2.5 mm | 1212250-18 | 1212250-28 | 1212250-38 | 5F (0.070"/1.8 mm) | 3.0 mm | 9/16 ATM |
3.0 mm | 1212300-18 | 1212300-28 | 1212300-38 | 5F (0.070"/1.8 mm) | 3.5 mm | 9/16 ATM |
3.5 mm | 1212350-18 | 1212350-28 | 1212350-38 | 5F (0.070"/1.8 mm) | 4.0 mm | 9/16 ATM |
3.75 mm | 1212375-18 | 1212375-28 | 1212375-38 | 5F (0.070"/1.8 mm) | 4.25 mm | 9/16 ATM |
Diameter | 18 | 28 | 38 | Sheath (F)1 | Maximum Post-Dilation Diameter1 | Nominal/RBP Inflation Pressure1 |
---|---|---|---|---|---|---|
2.5 mm | 1203250-18 | 1203250-28 | 1203250-38 | 5F (0.070"/1.8 mm) | 3.0 mm | 9/16 ATM |
3.0 mm | 1203300-18 | 1203300-28 | 1203300-38 | 5F (0.070"/1.8 mm) | 3.5 mm | 9/16 ATM |
3.5 mm | 1203350-18 | 1203350-28 | 1203350-38 | 5F (0.070"/1.8 mm) | 4.0 mm | 9/16 ATM |
3.75 mm | 1203375-18 | 1203375-28 | 1203375-38 | 5F (0.070"/1.8 mm) | 4.25 mm | 9/16 ATM |
Esprit™ BTK Everolimus Eluting Resorbable Scaffold Instructions for Use (IFU). Refer to IFU for additional information.
Beyond the treatment, make sure your referring physicians are fully aware of PAD and CLTI and how they can help with early diagnosis and timely treatment. For information specifically for the physician, visit our Clear Program webpage. Access a full range of helpful tools and insights. And for your patients, refer them to the PAD-info.com link to support the work you do, so they can learn about PAD symptoms and access an educational brochure.
MAT-2403385 v5.0
The Esprit™ BTK Everolimus Eluting Resorbable Scaffold System is indicated for improving luminal diameter in infrapopliteal lesions in patients with chronic limb-threatening ischemia (CLTI) and total scaffolding length up to 170 mm with a reference vessel diameter of ≥ 2.5 mm and ≤ 4.00 mm.
The Esprit™ BTK Everolimus Eluting Resorbable Scaffold System is contraindicated for use in:
Potential adverse events include, but are not limited to:
Allergic reaction or hypersensitivity to contrast agent, anesthesia, scaffold materials (poly[L-lactide] [PLLA], poly[D, L-lactide] [PDLLA], platinum, or everolimus), and drug reactions to anticoagulation or antiplatelet drugs
The risks described below include the anticipated adverse events referenced in the contraindications, warnings, and precautions sections of the everolimus labels / SmPCs and / or observed at incidences ≥ 10% in clinical trials with oral everolimus for different indications. Refer to the drug SmPCs and labels for more detailed information and less frequent adverse events.
There may be other potential adverse events that are unforeseen at this time.
MAT-2403616 v1.0
Stay Connected